Dhavalkumar M Patel

US Patent:

7662573, Feb 16, 2010

Filed:

Aug 12, 2005

Appl. No.:

11/573711

Inventors:

Shari M. Ling - Ellicott City MD, US
Lorah Perlee - Wilton CT, US
Velizar T. Tchernev - Sofia, BG
Dhavalkumar D. Patel - Chapel Hill NC, US
Luigi Ferrucci - Baltimore MD, US
Ming Zhan - Germantown MD, US

Assignee:

The United States of America as represented by the Department of Health and Human Services - Washington DC

International Classification:

G01N 33/53
C07K 14/435
C12P 19/34
C12Q 1/68

US Classification:

435 71, 435 72, 435 911, 435 912, 435183, 435 6, 530350, 530351

Abstract:

Methods are provided for evaluating osteoarthritis (OA), for example for diagnosing OA, to confirm a diagnosis of OA, to assess or prognose progression of OA, determining the severity of a subject who has OA, and determining a subject's risk of developing OA in the future, as are arrays and kits that can be used to practice the methods. In particular examples, the method includes determining an amount of activity (such as an amount of protein present or an amount of expression) of OA risk-related molecules, such as soluble vascular adhesion protein 1 (sVAP-1) or interleukin-15 (IL-15). Also provided are methods of identifying one or more compounds that alter the activity of an OA-related molecule, thereby identifying potential anti-osteoarthritis drugs.

US Patent:

20040009503, Jan 15, 2004

Filed:

Mar 26, 2003

Appl. No.:

10/396317

Inventors:

Qin Fu - Baltimore MD, US
Velizar Tchernev - Branford CT, US
Ebenezer Satyaraj - Hamden CT, US
Dhavalkumar Patel - Durham NC, US
Stephen Kingsmore - Guilford CT, US
Barry Schweitzer - Woodbridge CT, US

Assignee:

Molecular Staging, Inc. - New Haven CT

International Classification:

C12Q001/68

US Classification:

435/006000

Abstract:

Human extracellular ribonucleases (RNases) are widely distributed in various organs and body fluids and together with other members of the mammalian RNase A superfamily. In addition to their RNase activity, several RNases have been shown to have special biological actions, i.e., antitumor, antiviral and angiogenic properties. However, the molecular mechanisms of such activities are unclear. Using protein microarrays amplified rolling circle amplification (RCA), we investigated the effects of EDN (Rnase 2), ECP (Rnase 3) and RNase 1 on leukocytes cytokine production. We measured the levels of 78 different cytokines and growth factors in culture supernatants to determine the cytokine profiles of cells treated with different combinations of RNases and RNase inhibitors. Members of human ribonuclease family (such as Rnase 1, hEDN (Rnase 2) and Rnase 3) induced expression of certain sets of cytokines in human leukocytes, including ENA-78, EOT2, BLC, GDNF, 1309, IFN-, IFN-, IL-10, IL-12P40, IL-12p70, IL-13, IL-16, IL-18, IL-1, IL-1ra, IL-2Sra, IL-3, IL-6, IL-6sR, IL-7, IL-8, IP-10, MCP-1, MCP-2, MCP-3, MCSF, MIG, MDC, MIP-1, MIP-1, MPIF-1, NAP-2, RANTES, sCD23, OSM, TARC, TNF-, TNF-R1 and uPAR. Thus members of the Rnase superfamily are therapeutic targets for treatment of inflammatory diseases and clinical conditions. Inhibition or augmentation of Rnase expression is used to modulate the immune system and is beneficial for host defense against various diseases and is exploited as an adjuvant. The expression of Rnases is a diagnostic marker for inflammation related conditions and is used to determine various disease stages. In addition, expression of cytokines, chemokines, growth factors is used to monitor efficacy of Rnase-base therapies.

US Patent:

20040101510, May 27, 2004

Filed:

Sep 12, 2003

Appl. No.:

10/660734

Inventors:

Qin Fu - Baltimore MD, US
Velizar Tchernev - Branford CT, US
Ebenezer Satyaraj - Hamden CT, US
Dhavalkumar Patel - Chapel Hill NC, US
Stephen Kingsmore - Guilford CT, US

Assignee:

Molecular Staging Inc. - New Haven CT

International Classification:

A61K038/19

US Classification:

424/085100

Abstract:

We measured the levels of 78 different cytokines and growth factors in culture supernatants to determine the cytokine profiles of cells treated with PARC. We found that specific cytokines were suppressed by PARC. PARC can be used to treat diseases such as cancer, autoimmune diseases, rheumatoid arthritis, myeloproliferative disorders, and coronary artery disease, which are characterized by too much mitosis.

US Patent:

20100150838, Jun 17, 2010

Filed:

Dec 24, 2009

Appl. No.:

12/647166

Inventors:

Shari M. Ling - Ellicott City MD, US
Lorah Perlee - Wilton CT, US
Velizar T. Tchernev - Sofia, BG
Dhavalkumar D. Patel - Chapel Hill NC, US
Luigi Ferrucci - Baltimore MD, US
Ming Zhan - Germantown MD, US

International Classification:

A61K 49/00
C12Q 1/68
C40B 30/04
C40B 40/10
G01N 33/68
A61K 31/7008
A61K 31/60
A61K 31/192
A61K 31/4025
A61K 31/167
A61K 31/737
A61K 31/65

US Classification:

424 91, 435 6, 506 9, 506 18, 435 71, 514 62, 514165, 514570, 514569, 514411, 514629, 514 54, 514152

Abstract:

Methods are provided for evaluating osteoarthritis (OA), for example for diagnosing OA, to confirm a diagnosis of OA, to assess or prognose progression of OA, determining the severity of a subject who has OA, and determining a subject's risk of developing OA in the future, as are arrays and kits that can be used to practice the methods. In particular examples, the method includes determining an amount of activity (such as an amount of protein present or an amount of expression) of OA risk-related molecules, such as soluble vascular adhesion protein 1 (sVAP-1) or interleukin-15 (IL-15). Also provided are methods of identifying one or more compounds that alter the activity of an OA-related molecule, thereby identifying potential anti-osteoarthritis drugs.